Fennec Pharmaceuticals is a small stage biotechnology company focused on the development of PEDMARK TM (a unique formulation of Sodium Thiosulfate) for the prevention of ototoxicity from cisplatin in pediatric patients.
PEDMARK is an investigational drug and has not yet been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.
Publications & Presentations
Helping the Kids of Today Become the Adults of Tomorrow
Hearing loss is a devastating and life-long impact on quality of life for children that can cause grade setbacks and learning problems. Fennec advocates for a better quality of life.
Fennec News
- March 5th, 2020 FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARK™
- February 28th, 2020 Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate
- February 14th, 2020 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2019 FINANCIAL RESULTS